Curanex Pharmaceuticals (CURX) Q2 2026 earnings summary

Executive summary

• Focused on developing botanical drugs for inflammatory diseases, with Phyto-N as the lead candidate targeting ulcerative colitis and other indications.

• Expanded pipeline to include cancer cachexia as a new core indication, diversifying long-term therapeutic focus.

• Completed initial public offering (IPO) in August 2025, raising net proceeds of $13.24 million, with an additional $2.07 million from over-allotment.

• No revenue generated; operations funded by equity and debt issuances.

Financial highlights

• Net loss for Q2 2026 was $3,290,970, compared to $60,346 in Q2 2025.

• Net loss for the six months ended June 30, 2026 was $6,441,198, up from $197,929 for the same period in 2025.

• Cash and cash equivalents as of June 30, 2026 were $2,938,463, down from $4,973,134 at December 31, 2025.

• Accumulated deficit reached $11,288,753 as of June 30, 2026.

• R&D expenses for the six months ended June 30, 2026 totaled $4,849,879; general and administrative expenses were $1,659,040.

Outlook and guidance

• Plans to submit an IND for ulcerative colitis in Q4 2026, with Phase I trial to follow pending FDA approval.

• Expects R&D expenditures and cash requirements to increase as prepaid balances are consumed and clinical activities ramp up.

• Current cash is not sufficient to fund operations for the next twelve months; additional capital will be required.